These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10974350)

  • 1. Plasminogen and tissue plasminogen activator interact with antithrombin III.
    Dudani AK
    Thromb Res; 2000 Sep; 99(6):635-41. PubMed ID: 10974350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator.
    Moser TL; Enghild JJ; Pizzo SV; Stack MS
    J Biol Chem; 1993 Sep; 268(25):18917-23. PubMed ID: 8360181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation.
    Liang JF; Li Y; Yang VC
    Thromb Res; 2000 Mar; 97(5):349-58. PubMed ID: 10709911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of fucoidan with proteases and inhibitors of coagulation and fibrinolysis.
    Minix R; Doctor VM
    Thromb Res; 1997 Sep; 87(5):419-29. PubMed ID: 9306616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin.
    Parkkinen J; Rauvala H
    J Biol Chem; 1991 Sep; 266(25):16730-5. PubMed ID: 1909331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor.
    Kost C; Benner K; Stockmann A; Linder D; Preissner KT
    Eur J Biochem; 1996 Mar; 236(2):682-8. PubMed ID: 8612645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasmin.
    Torr-Brown SR; Nachowiak D; Fujii S; Sobel BE
    Coron Artery Dis; 1994 Jul; 5(7):625-31. PubMed ID: 7952425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen.
    Andrade-Gordon P; Strickland S
    Biochemistry; 1986 Jul; 25(14):4033-40. PubMed ID: 2943315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a).
    Dudani AK; Ganz PR
    Br J Haematol; 1996 Oct; 95(1):168-78. PubMed ID: 8857956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the strength of binding of antithrombin III, protamine and poly(L-lysine) to heparin samples of different anticoagulant activities.
    Jones GR; Hashim R; Power DM
    Biochim Biophys Acta; 1986 Aug; 883(1):69-76. PubMed ID: 3730427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific binding of plasminogen to vitronectin. Evidence for a modulatory role of vitronectin on fibrin(ogen)-induced plasmin formation by tissue plasminogen activator.
    Preissner KT
    Biochem Biophys Res Commun; 1990 May; 168(3):966-71. PubMed ID: 1693270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceleration of plasminogen activation by tissue plasminogen activator on surface-bound histidine-proline-rich glycoprotein.
    Borza DB; Morgan WT
    J Biol Chem; 1997 Feb; 272(9):5718-26. PubMed ID: 9102401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the N-terminal region of staphylokinase (SAK): evidence for the participation of the N-terminal region of SAK in the enzyme-substrate complex formation.
    Rajamohan G; Dikshit KL
    FEBS Lett; 2000 Jun; 474(2-3):151-8. PubMed ID: 10838076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin.
    Pâques EP; Stöhr HA; Heimburger N
    Thromb Res; 1986 Jun; 42(6):797-807. PubMed ID: 3088755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavior of antithrombin III isoforms on immobilized heparins. Evidence that the isoforms bind to different numbers of low-affinity heparin sites.
    Carlson TH; Babcock T; Atencio AC; Levinson C; Mora HR
    J Biol Chem; 1988 Feb; 263(5):2187-94. PubMed ID: 3339006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridoxylation of essential lysines in the heparin-binding site of antithrombin III.
    Pecon JM; Blackburn MN
    J Biol Chem; 1984 Jan; 259(2):935-8. PubMed ID: 6420409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.